Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aclarion Inc (ACON)

Aclarion Inc (ACON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,785
  • Shares Outstanding, K 854
  • Annual Sales, $ 50 K
  • Annual Income, $ -6,990 K
  • EBIT $ -7 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.44
  • Price/Sales 37.32
  • Price/Cash Flow N/A
  • Price/Book 0.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -2.79
  • Number of Estimates 1
  • High Estimate -2.79
  • Low Estimate -2.79
  • Prior Year -9.32
  • Growth Rate Est. (year over year) +70.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.46 +30.08%
on 02/24/26
3.52 -9.09%
on 03/10/26
+0.66 (+25.98%)
since 02/20/26
3-Month
2.34 +36.75%
on 02/05/26
9.36 -65.81%
on 01/08/26
-3.00 (-48.39%)
since 12/19/25
52-Week
2.34 +36.75%
on 02/05/26
21.32 -84.99%
on 03/24/25
-18.40 (-85.19%)
since 03/20/25

Most Recent Stories

More News
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 ...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc .,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),  a commercial-stage healthcare technology company that is leveraging...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion CEO Brent Ness to Attend LSI USA 2026

BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc .,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),  a commercial-stage healthcare technology company that is leveraging...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion Publishes 2026 Shareholder Letter from the Chairman

Company anticipates no capital raises prior to expected value enhancing catalysts  Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo.,...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Expands availability of Nociscan in the greater Los Angeles area Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion Provides 2025 Update and 2026 Corporate Outlook

Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine...

ACONW : 0.0364 (+9.64%)
ACON : 3.20 (-1.84%)

Business Summary

Aclarion Inc. is a healthcare technology company which leverages Magnetic Resonance Spectroscopy and a proprietary biomarker to optimize clinical treatments. The Company is also researching the application of AI and machine learning platforms to analyze both the raw spectroscopy data and the post-processed...

See More

Key Turning Points

3rd Resistance Point 3.45
2nd Resistance Point 3.34
1st Resistance Point 3.27
Last Price 3.20
1st Support Level 3.09
2nd Support Level 2.98
3rd Support Level 2.91

See More

52-Week High 21.32
Fibonacci 61.8% 14.07
Fibonacci 50% 11.83
Fibonacci 38.2% 9.59
Last Price 3.20
52-Week Low 2.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.